0001906324false00019063242024-12-062024-12-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 6, 2024

QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)

Delaware
001-41409

87-4496285
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
(858552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 6, 2024, the Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) appointed John R. Chiminski and R. Scott Huennekens as directors, effective as of December 6, 2024. A copy of the press release issued in connection with the appointment of these directors is attached hereto as Exhibit 99.1. Each of Messrs. Chiminski and Huennekens qualifies as an “independent director” under the applicable rules of The Nasdaq Stock Market LLC.

There are no arrangements or understandings between each of Messrs. Chiminski and Huennekens and any other persons pursuant to which he was selected as a director. There are no family relationships between each of Messrs. Chiminski and Huennekens and any director or executive officer of the Company, and each of Messrs. Chiminski and Huennekens has no direct or indirect material interest in any transaction that would require disclosure pursuant to Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Form 8-K:

Exhibit Number
Description of Exhibit
99.1
104
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 10, 2024
   
QUIDELORTHO CORPORATION
  
By:/s/ Michelle A. Hodges 
Name:Michelle A. Hodges 
Its:Secretary 






Exhibit 99.1
image_0.jpg


QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board

December 10, 2024
SAN DIEGO -- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the “Board”), effective December 6, 2024.
These appointments align with QuidelOrtho’s commitment to maintaining a strong, independent Board with the right mix of expertise and experience. These appointments are the culmination of a comprehensive search led by the Board’s Nominating and Corporate Governance Committee and supported by an independent executive search firm.
“We are excited to welcome John and Scott to our Board,” said Kenneth F. Buechler, Ph.D., Chairman of the Board. “They bring proven track records of growth and value creation as CEOs and board members of healthcare, biopharma and MedTech companies. We are confident they will be significantly additive to the Board as we work with management to continue their positive momentum in executing QuidelOrtho’s growth and transformation plans and in creating further shareholder value.”
"I believe QuidelOrtho’s best days lie ahead as we strengthen our leadership team and Board. Both John and Scott bring valuable global experience, diverse expertise and a broad perspective that will be assets to the Company,” said Brian J. Blaser, President and CEO, QuidelOrtho. “I look forward to benefiting from their guidance and partnership as we execute our transformational strategy, deliver enhanced financial results and bring forth innovative technologies that raise the performance of diagnostic testing and produce better patient outcomes.”
As a former CEO and board Chair, Mr. Chiminski brings a diversified medical diagnostics and pharmaceutical background, which includes operations leadership, product development and services, and a strong track record of growing global businesses. He served as CEO of Catalent (NYSE: CTLT) from 2009 to 2022, assumed the title of Chair of its board of directors in 2016, and served as Executive Chair from 2022 to 2023. He was instrumental in establishing Catalent as a standalone public company after its carve-out from Cardinal Health and transforming the company into a market leader in biopharma services. Prior to that, Mr. Chiminski spent more than 20 years with GE Healthcare in roles of increasing responsibility, ultimately serving as President and CEO of GE Medical Diagnostics, a global business with $1.9 billion in sales.
Mr. Huennekens is a successful MedTech CEO, Chair, board member, entrepreneur and investor and has been involved in over 20 startups and public companies. He served as Chair, President and CEO of Verb Surgical, an independent surgical technology start-up jointly formed by Google and Johnson & Johnson, from 2015 to 2019. Prior to Verb Surgical, he was President and CEO at Volcano Corporation, a leader in minimally invasive therapy guidance in interventional cardiology, and prior to that, President and CEO at Digirad Corporation, a coronary imaging solutions provider. Previously, Mr. Huennekens held various leadership positions at Baxter Healthcare, Birtcher Medical Systems and Deloitte and Touche. He currently serves as Chair of the board of directors of Envista Holdings (NYSE: NVST) and as Chair of the board of directors of Hyperfine (Nasdaq: HYPR).
1




As previously announced, James R. Prutow and Robert R. Schmidt resigned from the Board, effective November 21, 2024, in conjunction with the closing of the secondary offering of QuidelOrtho common stock by The Carlyle Group. With the appointments of Messrs. Chiminski and Huennekens, the Board will comprise 11 directors, 10 of whom are independent.
Dr. Buechler added, “On behalf of the Board, I also want to acknowledge James and Robert for their insights and contributions. We thank them for their service to the Company.”
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects, and a more informed path is illuminated for each of us.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
2
v3.24.3
Document and Entity Information Document
Dec. 06, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 06, 2024
Entity Incorporation, State or Country Code DE
Entity File Number 001-41409
Entity Tax Identification Number 87-4496285
Entity Address, Address Line One 9975 Summers Ridge Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 552-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol QDEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001906324
Amendment Flag false
Entity Registrant Name QUIDELORTHO CORP

Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di QuidelOrtho
Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di QuidelOrtho